Xenon Pharmaceuticals Inc. (XENE)
$34.42-3.88%Close
SELLCRISIS · day 18
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3.3B
- Beta
- 0.60
- P/E (TTM)
- -7.26
- Short % float
- 6.66%
- Days to cover
- 1.6
- SI change
- -6.3%
- 1W
- -5.88%
- 1M
- -40.85%
- vs SPY 1W
- -5.74%
- vs SPY 1M
- -43.35%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$14.6BRECOVERYQ 16$145.51-4.41%
- JAZZSELLJazz Pharmaceuticals plc$14.5BBEARQ 24$231.39-2.93%
- AXSMSELLAxsome Therapeutics, Inc.$9.0BCRISISQ 34$174.34-5.83%
- PRAXSELLPraxis Precision Medicines, Inc.$7.8BCRISISQ 11$280.14-3.20%
- ACADSELLAcadia Pharmaceuticals Inc.$3.4BCRISISQ 17$19.74-4.07%
- DNLISELLDenali Therapeutics Inc.$3.1BCRISISQ 8$19.28-2.90%
- SUPNBUYSupernus Pharmaceuticals, Inc.$2.5BRECOVERYQ 26$42.83-1.87%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 24$31.15-3.85%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on XENE?
- LOPJLB’s latest quantitative signal on Xenon Pharmaceuticals Inc. (XENE) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is XENE in?
- Xenon Pharmaceuticals Inc. (XENE) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Xenon Pharmaceuticals Inc. (XENE) do?
- Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase…